| Similar Articles |
|---|
 |
The Motley Fool
August 10, 2005
Stephen D. Simpson |
A Greatbatch of High Energy Strong demand for implanted medical devices continues to spark growth for this battery and electrical component maker. The stock does offer a fairly unique way to play multiple growing medical markets.   |
The Motley Fool
November 9, 2005
Stephen D. Simpson |
Greatbatch Keeps Growth Pumping Demand for implantable medical electronics keeps this battery and component maker humming. Investors new to this stock and/or medical technology in general will need to exercise some patience. |
The Motley Fool
February 23, 2006
Stephen D. Simpson |
A Nasty Jolt to Greatbatch Disappointing margins take a bite out of the company's market cap. While valuation here is a bit difficult, any way you slice it, the stock doesn't look too interesting. |
The Motley Fool
July 22, 2011 |
Greatbatch Earnings Preview Medical device maker Greatbatch will unveil its latest earnings on Wednesday, July 27. |
The Motley Fool
May 24, 2006
S.J. Caplan |
Goodbye, Guidant Publicity woes drive Boston Scientific to ditch the Guidant name. In the meantime, Boston Scientific wants to capitalize on its entry into the ICD market, an area experiencing double-digit sales growth. Investors, take note. |
IndustryWeek
January 1, 2009
Jill Jusko |
Greatbatch: IW Best Plants Profile 2008 Leading with Lean: At Greatbatch, continuous improvement never takes a back seat. |
The Motley Fool
August 15, 2005
Rick Aristotle Munarriz |
3 Stocks That Blew the Market Away Beat your targets as a public company and capital appreciation almost always follows: JAMDAT... Greatbatch... Echostar... |
The Motley Fool
August 3, 2006
Stephen D. Simpson |
Asymmetrical Medical It may pay for investors to be patient with this med-tech company while the industry is in a rough patch. |
IndustryWeek
January 1, 2009
Jill Jusko |
2008 IW Best Plants Winners: Winning Ways IndustryWeek's 2008 Best Plants winners make excellence an everyday event. Read on for the full list. |
The Motley Fool
January 25, 2006
Stephen D. Simpson |
Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note. |
The Motley Fool
April 19, 2006
Stephen D. Simpson |
St. Jude Lives and Learns Though dynamics in the ICD market caught it by surprise, this is still a quality med-tech company. Investors, take note. |
The Motley Fool
June 29, 2006
Jim Mueller |
Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition. |
